Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies - Mullins, Garrett R; Hodsdon, Michael E; Li, Ying Grace; Anglin, Greg; Urva, Shweta; Schneck, Karen; Bardos, Jennifer N; Martins, Ricardo Fonseca; Brown, Katelyn; Calderon, Boris (The journal of clinical endocrinology and metabolism, 2024)
Keywords: Antibodies; Antibodies, Neutralizing; Biological products; Care and treatment; Clinical; Clinical trials; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Gastric Inhibitory Polypeptide - therapeutic use; GIP protein; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide 1 - therapeutic use; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide-2 Receptor; Humans; Hypersensitivity; Hypoglycemic agents; Hypoglycemic Agents - adverse effects; Immunogenicity; Injection; Injection Site Reaction; Pharmaceutical industry; Pharmacokinetics; Product development; Type 2 diabetes; Viral antibodies; United States; Japan; clinical trial; type 2 diabetes; incretin therapy; immunogenicity